Loading clinical trials...

Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT02725437

Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults

The first-in-Japanese study B5091010 has been designed to evaluate the safety, tolerability, and immunogenicity of 2 antigen dose levels of C difficile vaccine when administered as one of two 3-dose r...

Lead sponsor: Pfizer•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 3

Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study

NCT03918629 · Clostridium Difficile Associated Disease

COMPLETEDPhase 3

Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age

NCT03579459 · Clostridium Difficile Associated Disease

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 13, 2018Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment100

Start dateFeb 2016

Last updatedJul 13, 2018

Condition

Clostridium Difficile Associated Disease

Locations shown

SOUSEIKAI Sumida Hospital (formerly Medical Co. LTA Sumida Hospital)

Sumida-ku, Tokyo

SOUSEIKAI PS Clinic (formerly Medical Co. LTA PS Clinic)

Fukuoka

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 13, 2018Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions